PT-141 is bremelanotide, an approved drug prescribed under the brand name Vyleesi for premenopausal women with low sexual desire. At Longevity Benchmark, we read the approved label before the marketing, and we report who a product is not for. The compound operates as a melanocortin receptor agonist. PT-141 is frequently discussed as a libido or erectile-dysfunction peptide. Federal documentation tells a narrower story.
The Verdict
What PT-141 Is and Who Its Label Covers
PT-141 is bremelanotide, marketed as the prescription drug Vyleesi. The drug is classified pharmacologically as a melanocortin receptor agonist. Regulatory authorities approved the molecule to treat premenopausal women who experience acquired, generalized hypoactive sexual desire disorder (HSDD). The official drug label published on DailyMed defines the legal scope of its clinical administration.
According to the official Indications and Usage section, the drug treats low sexual desire that causes marked distress or interpersonal difficulty. The condition cannot stem from an underlying medical disorder, psychiatric diagnosis, relationship conflict, or medication side effect. The label confines therapy strictly to patients who meet every diagnostic criterion.
The label also contains mandatory Limitations of Use. The text reads: "Not indicated for treatment of HSDD in postmenopausal women or in men. Not indicated to enhance sexual performance." This statement restricts the compound from the exact applications most commonly discussed online. Regulatory clearance does not cover male sexual health or recreational enhancement.
| Clinical Parameter | Approved Label Specification | Regulatory Boundary |
|---|---|---|
| Drug Identity | Bremelanotide (PT-141), brand name Vyleesi | Melanocortin receptor agonist |
| Approved Population | Premenopausal women with acquired generalized HSDD | Causes marked distress or interpersonal difficulty |
| Excluded Populations | Men and postmenopausal women | Explicitly barred in Limitations of Use |
| Excluded Purpose | Enhancement of sexual performance | Not indicated, per the label's Limitations of Use |
The Indication and Its Statutory Exclusions
The approved indication for bremelanotide requires sexual desire loss to be both acquired and generalized. An acquired condition means the individual experienced normal sexual desire previously. Generalized means the deficit occurs across all sexual situations rather than with a specific partner. The low desire must produce significant distress or interpersonal friction.
Federal labeling establishes three mandatory exclusions. Low desire must not be due to a co-existing medical or psychiatric condition.
The second exclusion removes cases caused by relationship problems. Difficulties between partners fall outside the pharmacological scope of the drug. The third exclusion removes low desire caused by medication effects or drug substances. If an exogenous substance causes the symptom, bremelanotide is not clinically indicated.
Label Limitations for Men and Performance Use
Federal product labeling explicitly excludes men from the clinical population approved for bremelanotide therapy. The official product insert directly contradicts that application. No regulatory agency has approved bremelanotide to treat male hypoactive sexual desire or male erectile dysfunction.
The exclusion against performance enhancement is equally direct. The drug insert states unequivocally that the product is not indicated to enhance sexual performance. Healthy individuals without diagnosed hypoactive sexual desire disorder have no approved basis for taking the compound.
A reader who arrived here because desire or energy has changed is usually asking a hormone question rather than a peptide one, and this site answers that separately for men and in perimenopause.
Cardiovascular Warnings and Blood Pressure Responses
Bremelanotide produces predictable hemodynamic changes after administration. Clinical pharmacology data confirm that the drug induces a transient increase in blood pressure alongside a transient reduction in heart rate. These cardiovascular changes typically resolve within 12 hours after dosing. The label therefore includes specific cardiovascular warnings and precautions.
The prescribing information lists two explicit contraindications. Patients with uncontrolled hypertension cannot receive the medication. Individuals with known cardiovascular disease are likewise barred from use. Prescribers must assess underlying cardiovascular risk factors before writing a prescription. The label states clearly that the drug is not recommended in patients at high risk for cardiovascular disease.
Dermatological side effects also appear in the prescribing record. Clinical trials documented focal hyperpigmentation in 1% of patients who received up to 8 doses of the medication.
| Safety Category | Label Finding or Mandate | Clinical Consequence |
|---|---|---|
| Contraindications | Uncontrolled hypertension or known cardiovascular disease | Contraindicated per the approved label |
| Hemodynamic Shifts | Transient increase in blood pressure, decrease in heart rate | Shifts typically resolve within 12 hours |
| Cardiovascular Risk | Not recommended in patients at high risk for heart disease | Label directs prescribers to ensure blood pressure is well controlled |
| Dermatological Event | Focal hyperpigmentation reported in 1% of patients | Observed in individuals receiving up to 8 doses |
Compounding Category Lists and Regulatory Channels
Bremelanotide occupies a distinct regulatory position compared to unapproved research peptides. The compound does not appear on the FDA compounding bulk-substance lists. It is absent from the Category 2 list of substances that present significant safety risks. It is also absent from the list of nominated substances that sponsors later withdrew.
This absence occurs because an approved commercial product already exists. An approved product follows a different regulatory route entirely from compounding a bulk substance. Readers comparing clinical peptides can review our complete index of peptide therapy FDA approval status across major compounds.
Commercial drug channels differ fundamentally from unregulated online vendors. Vials purchased through research peptide sites do not represent the approved drug product. Nothing in the regulatory record validates the chemical identity, purity, or actual content of substances sold outside licensed pharmacy channels. Compounding rules and prescription pricing are explored further in our guide to peptide therapy costs and pharmacy dispensing.
The RECONNECT Trial Registration Program
The clinical registration program supporting the approval of bremelanotide was conducted under the name RECONNECT. This clinical program consisted of phase 3 clinical trials. Investigators enrolled premenopausal women who satisfied the strict diagnostic criteria for acquired, generalized HSDD. The trials evaluated changes in sexual desire scores and distress markers.
The RECONNECT trials were designed specifically to measure psychological distress and self-reported desire. Readers interested in trial metrics, score shifts, and statistical outcomes can read our detailed review of the RECONNECT trial results on libido and distress. The trials did not evaluate men.
What the Registration Trials Measured, and What They Found
The registration trials demonstrated small numerical gains on two subjective survey scores, but they failed to increase sexual events. In the pivotal phase 3 trials, bremelanotide achieved a statistically significant 0.35-point increase on the FSFI Desire scale, which runs from 1.2 to 6.0. The drug also produced a 0.33-point reduction in distress.
The secondary behavioural endpoint was null. The FDA label states explicitly that there was "no significant difference between treatment groups in the change from baseline in satisfying sexual events."
Across the trials, 39% to 40% of patients discontinued treatment early due to adverse events, against 13% to 25% on placebo. Nausea, flushing, and headache primarily drove those early discontinuations. The drug was approved on movement in two questionnaire scores while the endpoint that counts events did not move.
A 0.35-point shift on a 1.2-to-6.0 scale remains a small movement on a self-reported instrument. The full trial data and external source citations appear in our review of libido therapies and trial endpoints.
Populations Excluded from the Evidence Base
The clinical evidence base for bremelanotide excludes the vast majority of demographic groups. Men represent the most notable excluded population. There is no approved bremelanotide product or clinical indication for men. The product insert states plainly that the compound is not indicated for men.
Postmenopausal women represent another explicitly excluded group. The label explicitly states that the drug is not indicated for treatment of HSDD in postmenopausal women. Individuals with cardiovascular conditions, unmanaged hypertension, or low desire driven by marital distress also fall completely outside the indicated population.
Conditions That Would Change This Regulatory Assessment
Our assessment of PT-141 rests on current federal approvals, product labeling, and published trial boundaries. This evaluation would change if pharmaceutical sponsors completed prospective phase 3 clinical trials in male populations. If those trials demonstrated clinical efficacy for erectile dysfunction or male desire disorders, and the FDA granted an approved supplemental indication, the scope of the drug would broaden.
A second shift would occur if regulators approved the peptide for postmenopausal sexual desire disorders. That approval would require distinct clinical trial data addressing postmenopausal physiology. Until peer-reviewed registration trials produce new approvals, bremelanotide remains indicated solely for premenopausal acquired generalized HSDD.
Frequently Asked Questions
What is PT-141 used for?
PT-141, known chemically as bremelanotide, is indicated exclusively for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Federal labeling requires that the low sexual desire causes marked distress or interpersonal difficulty. The diagnosis cannot be due to a co-existing medical condition, psychiatric disorder, relationship problem, or the side effects of another medication. The drug is approved as the prescription brand Vyleesi and functions as a melanocortin receptor agonist. It is not approved for any other medical use.
Is PT-141 for men or women?
PT-141 is approved only for premenopausal women. The official FDA-approved drug label contains an explicit Limitations of Use section that states the medication is not indicated for treatment of HSDD in men or in postmenopausal women. The label also warns that the compound is not indicated to enhance sexual performance. There is no approved bremelanotide product for erectile dysfunction, for men, for postmenopausal women, or for enhancing sexual performance.
What does PT-141 do for men?
Bremelanotide has no approved indication, validated clinical dosage, or verified therapeutic role for men. The federal product label explicitly states that the drug is not indicated for men or for enhancing sexual performance. The label's warnings and precautions include transient increases in blood pressure, decreases in heart rate, and focal hyperpigmentation.
Is PT-141 FDA approved?
Yes, PT-141 is FDA approved under the generic chemical name bremelanotide and the proprietary brand name Vyleesi. The approval is limited strictly to premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder. However, unbranded vials of PT-141 sold across the internet as research chemicals are not approved drug products. Products bought outside a prescription lack established identity, purity, or content.
Does PT-141 work?
The pivotal phase 3 trials moved the two questionnaire scores they were powered for and missed the endpoint that counted events. Bremelanotide produced a statistically significant 0.35-point increase on the FSFI Desire scale, which runs from 1.2 to 6.0, and a 0.33-point reduction in distress. The FDA label then states explicitly that there was no significant difference between treatment groups in the change from baseline in satisfying sexual events. Between 39% and 40% of participants stopped treatment early because of adverse events, against 13% to 25% on placebo, driven mainly by nausea, flushing and headache. So the approval rests on small movement in self-reported desire and distress rather than on a measured change in events. The fuller trial treatment, with its external sources, is in our review of libido therapies and trial endpoints.
Is PT-141 a peptide?
PT-141 is bremelanotide, marketed as Vyleesi, which acts as a melanocortin receptor agonist.
Is PT-141 safe?
Bremelanotide carries defined safety risks documented in its prescribing information. The medication causes a transient increase in blood pressure and a concurrent decrease in heart rate after each dose, which typically resolves within 12 hours. Because of these hemodynamic shifts, the drug is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Prescribing clinicians must assess cardiovascular risk prior to initiation. Clinical trials also documented focal hyperpigmentation in 1% of patients who received up to 8 doses.
Is PT-141 better than Viagra?
The two drugs carry different labelled indications in different populations, and bremelanotide's own label states it is not indicated for men or to enhance sexual performance. A head-to-head comparison has no published basis. Bremelanotide is a melanocortin receptor agonist approved strictly for female hypoactive sexual desire disorder. Its label explicitly states it is not indicated for men, nor is it indicated to enhance sexual performance.